Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385148 | 1.00 | TBXA2R (0.36) | TBXA2RSLC6A4SLC6A3SLC6A2PDE4D | |
| SCHEMBL14415439 | 1.00 | TBXA2R (0.36) | TBXA2RSLC6A4SLC6A3SLC6A2PDE4D | |
| SCHEMBL250155 | 0.87 | LMNA (0.41) | TBXA2RSLC6A4SLC6A3 | |
| SCHEMBL14415445 | 0.86 | SLC6A3 (0.35) | TBXA2RSLC6A4SLC6A3SLC6A2PDE4D | |
| SCHEMBL14415444 | 0.82 | KDM4E (0.35) | TBXA2RSLC6A4SLC6A3PDE4D | |
| SCHEMBL14415451 | 0.80 | TBXA2R (0.48) | TBXA2R | |
| SCHEMBL14415446 | 0.79 | TBXA2R (0.57) | TBXA2R | |
| SCHEMBL14415443 | 0.76 | TBXA2R (0.35) | TBXA2R | |
| SCHEMBL249279 | 0.76 | TBXA2R (0.40) | TBXA2R | |
| SCHEMBL249477 | 0.75 | TBXA2R (0.38) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273883-B2 | Prostaglandin EP4 antagonist | ALLERGAN, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7217725-B2 | Prostaglandin D2 antagonist | ALLERGAN, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050065200-A1 | Prostaglandin EP4 antagonist | ALLERGAN, INC. (US) | 2005-03-24 | — | — | US | disclosed |
| US-20040162323-A1 | Prostaglandin D2 antagonist | ALLERGAN, INC. | 2004-08-19 | — | — | US | disclosed |
| US-6716864-B2 | FOR THERAPY OF INFLAMMATORY REACTIONS RELATING TO RHEUMATOID ARTHRITIS AND PSORIASIS, REPRODUCTIVE DISORDERS, BRONCHOCONSTRICTIVE DISORDERS (ASTHMA), EXCESSIVE BONE BREAKDOWN (OSTEOPOROSIS), PEPTIC ULCERS, HEART DISEASE | ALLERGAN, INC. | 2004-04-06 | — | — | US | disclosed |
| US-20030105064-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | ALLERGAN INC. | 2003-06-05 | — | — | US | disclosed |
| US-6511999-B2 | Treating rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), osteoporosis, peptic ulcers, heart disease, and thrombosis | ALLERGAN, INC. | 2003-01-28 | — | — | US | disclosed |
| US-6509364-B2 | Antiinflammatory agents for reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, broncho-constrictive disorders, excessive bone breakdown, peptic ulcers, heart disease, platelet aggregation and thrombosis | ALLERGAN, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020165399-A1 | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists | ALLERGAN SALES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-20020128233-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | ALLERGAN, INC. | 2002-09-12 | — | — | US | disclosed |
| US-6407250-B1 | ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; OSTEOPOROSIS | ALLERGAN SALES, INC. | 2002-06-18 | — | — | US | disclosed |
| US-6369089-B1 | INFLAMMATORY REACTIONS RELATING TO RHEUMATOID ARTHRITIS AND PSORIASIS, REPRODUCTIVE DISORDERS, BRONCHOCONSTRICTIVE DISORDERS (ASTHMA), EXCESSIVE BONE BREAKDOWN (OSTEOPOROSIS), PEPTIC ULCERS, HEART DISEASE, PLATELET AGGREGATION AND | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165399-A1 | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists | PTGIR, PTGER1, TBXA2R | TBXA2R 3/4885SLC6A4 4720/4885SLC6A3 4862/4885 |
| US-20030105064-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | PTGER1, PTGIR, PTGDR | TBXA2R 7/4885SLC6A4 4571/4885SLC6A3 4811/4885 |
| US-20020128233-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | PTGER1, PTGIR, PTGDR | TBXA2R 6/4885SLC6A4 4578/4885SLC6A3 4833/4885 |
| US-20050065200-A1 | Prostaglandin EP4 antagonist | PTGER4, PTGER1, PTGER2 | TBXA2R 71/4885SLC6A4 368/4885SLC6A3 2110/4885 |
| US-20040162323-A1 | Prostaglandin D2 antagonist | PTGDR2, PTGDR, PTGS1 | TBXA2R 15/4885SLC6A4 1859/4885SLC6A3 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.